101931-31-1

Basic information

• Product Name: 4-METHOXYNAPHTHALEN-1-YLMETHYLAMINE
• Synonyms: 4-METHOXYNAPHTHALEN-1-YLMETHYLAMINE;RARECHEM AL BW 1108;(4-methoxynaphthalen-1-yl)methanamine;1-Naphthalenemethanamine, 4-methoxy-
• CAS NO: 101931-31-1
• Molecular Formula: C₁₂H₁₃NO
• Molecular Weight: 187.24
• Mol File: 101931-31-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 344.3±17.0 °C(Predicted)
• Appearance: /
• Density: 1.117±0.06 g/cm3(Predicted)
• PKA: 9.44±0.30(Predicted)
• CAS DataBase Reference: 4-METHOXYNAPHTHALEN-1-YLMETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXYNAPHTHALEN-1-YLMETHYLAMINE(101931-31-1)
• EPA Substance Registry System: 4-METHOXYNAPHTHALEN-1-YLMETHYLAMINE(101931-31-1)

Safety Data

• Hazardous Substances Data: 101931-31-1(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 122731-44-6 α-4-methoxy-naphthaldoxime-(1) 
• 15971-29-6 4-methoxy-1-naphthaldehyde 
• 5961-55-7 4-methoxy-1-naphthalenecarbonitrile 

Downstream Products

• 130750-68-4 4-Chloro-5-(4-methoxy-1-naphthylmethylamino)-3(2H)pyridazinone 

Relevant articles and documents

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of trypanosomatidae via structure-based drug design

In our continuation of the structure-based design of anti-trypanosomatid drugs, parasiteselective adenosine analogues were identified as low micromolar inhibitors of glyceraldehyde3-phosphate dehydrogenase (GAPDH). Crystal structures of Trypanosoma brucei, Trypanosoma cruzi, Leishmania mexicana, and human GAPDH's provided details of how the adenosyl moiety of NAD+ interacts with the proteins, and this facilitated the understanding of the relative affinities of a series of adenosine analogues for the various GAPDH's. From exploration of modifications of the naphthalenemethyl and benzamide substituents of a lead compound, N6-(1-naphthalenemethyl)-2′-deoxy-2′- (3-methoxybenzamido)adenosine (6e), N6-(substituted-naphthalenemethyl)-2′-deoxy-2′- (substituted-benzamido)adenosine analogues were investigated. N6(1 -Naphthalenemethyl)-2′-deoxy-2′-(3,5-dimethoxybenzamido)adenosine (6m), N6- [1-(3-hydroxynaphthalene)methyl]-2′-deoxy-2′- (3,5-dimethoxybenzamido)adenosine (7m), N6-[1-(3-methoxynaphthalene)methyl]-2′-deoxy-2′- (3,5-dimethoxybenzamido)adenosine (9m), N6-(2-naphthalenemethyl)-2′-deoxy-2′1- (3-methoxybenzamido)adenosine (11e), and N6-(2-naphthalenemethyl)-2′deoxy-2′- (3,5-dimethoxybenzamido)adenosine (11m) demonstrated a 2- to 3-fold improvement over 6e and a 7100- to 25000-fold improvement over the adenosine template. IC50'S of these compounds were in the range 2-12 μM for T. brucei, T. cruzi, and L. mexicana GAPDH's, and these compounds did not inhibit mammalian GAPDH when tested at their solubility limit. To explore more thoroughly the structure- activity relationships of this class of compounds, a library of 240 N6-(substituted)-2′-deoxy-2′-(amido)adenosine analogues was generated using parallel solution-phase synthesis with N6 and C2′ substituents chosen on the basis of computational docking scores. This resulted in the identification of 40 additional compounds that inhibit parasite GAPDH's in the low micromolar range. We also explored adenosine analogues containing 5′-amido substituents and found that 2′,5′-dideoxy-2′-(3,5-dimethoxybenzamido)-5′- (diphenylacetamido)adenosine (49) displays an IC50 of 60-100 μM against the three parasite GAPDH's.